重组人干扰素α1b联合雾化治疗对小叶性肺炎患儿血清炎性因子水平的影响OA
Recombinant human interferon α1b combined with nebulization therapy on serum inflammatory factor levels in children with bronchopneumonia
目的 探究重组人干扰素α1b联合雾化治疗对小叶性肺炎患儿的效果,为优化该疾病治疗方案提供循证依据.方法 采用计算机生成随机数字表法分组,并通过密闭信封法实施分配隐藏,将2023年7月至2025年10月福建省东山县医院收治的72例小叶性肺炎患儿分为两组,各36例.两组均实施基础抗感染对症方案,对照组采用盐酸左沙丁胺醇雾化吸入治疗,观察组在对照组基础上联合重组人干扰素α1b治疗,两组疗程均为7 d.比较两组临床疗效、临床症状及体征消失时间、血清炎性因子水平及不良反应发生率.结果 观察组总有效率高于对照组[97.22%(35/36)vs.77.78%(28/36),x²=4.571,P=0.033].观察组体温恢复正常、咳嗽和肺部啰音消失时间均短于对照组;在治疗前伴喘息患儿中,观察组喘息消失时间短于对照组(均P<0.001).治疗后,观察组血清IL-6、TNF-α和CRP水平均低于对照组(均P<0.001).观察组和对照组不良反应总发生率分别为13.89%和19.44%,差异无统计学意义(x²=0.400,P=0.527).结论 在基础治疗及盐酸左沙丁胺醇雾化吸入的基础上序贯雾化吸入重组人干扰素α1b可能有助于提高小叶性肺炎患儿的短期临床疗效、缩短临床症状及体征消失时间并降低治疗后炎性因子水平;小样本中未观察到不良反应发生率增加.
Objective To explore the effect of recombinant human interferon α1b combined with nebulization therapy on children with bronchopneumonia,and to provide evidence-based basis for optimizing the treatment plan for this disease.Methods Using the computer-generated random number table method for grouping and the sealed envelope method for allocation concealment,72 children with bronchopneumonia admitted to Dongshan County Hospital from July 2023 to October 2025 were divided into two groups,with 36 cases in each group.Both groups implemented the basic anti-infection and symptomatic treatment plan.The control group simply received nebulization inhalation therapy,while the observation group received recombinant human interferon α1b treatment in addition to the control group.The treatment course for both groups was 7 days.The clinical efficacy,clinical symptoms and signs relief time,serum inflammatory factor levels,and adverse reaction rates were compared between the two groups.Results The overall response rate was higher in the observation group than that in the control group[97.22%(35/36)vs.77.78%(28/36);x²=4.571,P=0.033].The times to normalization of body temperature and resolution of cough and pulmonary rales were shorter in the observation group than those in the control group.Among children with wheezing at baseline,the time to resolution of wheezing was also shorter in the observation group(all P<0.001).After treatment,serum IL-6,TNF-α,and CRP levels were lower in the observation group than those in the control group(all P<0.001).The overall incidence of adverse events was 13.89%in the observation group and 19.44%in the control group,with no significant between-group difference(x²=0.400,P=0.527).Conclusion Sequential nebulization with recombinant human interferon α1b in addition to basic treatment and nebulized levalbuterol may improve short-term clinical outcomes in children with bronchopneumonia.No increase in adverse events was observed in this small exploratory study.Larger studies are required to confirm these findings.
李寒梅;彭香
福建省东山县医院儿科,福建东山 363400福建省东山县医院儿科,福建东山 363400
小叶性肺炎重组人干扰素α1b雾化治疗炎性因子水平临床症状及体征消失时间
bronchopneumoniarecombinant human interferon α1bnebulization therapyinflammatory factor levelclinical symptoms and signs relief time
《中华灾害救援医学》 2026 (8)
908-912,5
评论